Scott Lohr
YOU?
Author Swipe
View article: Network propagation unveils molecular mechanisms modulated in Alzheimer’s Disease patients treated by the complex plasma fraction GRF6019
Network propagation unveils molecular mechanisms modulated in Alzheimer’s Disease patients treated by the complex plasma fraction GRF6019 Open
Background Our pre‐clinical work provided evidence of the interest of plasma fraction treatment to reverse age‐related cognitive decline. One of the most potent plasma fractions, GRF6019 was tested on patients with Alzheimer’s disease (AD)…
View article: Modulation of inflammatory regulation by plasma exchange with albumin replacement revealed by deep plasma and CSF proteomic profiling of the AMBAR study
Modulation of inflammatory regulation by plasma exchange with albumin replacement revealed by deep plasma and CSF proteomic profiling of the AMBAR study Open
Background AMBAR trial (phase 2b/3 clinical trial) evaluates plasma exchange efficacy with albumin replacement (PE‐Alb) in mild‐to‐moderate Alzheimer’s Disease (AD) patients. It includes an intensive period (IP) comprising 6‐weeks of conve…
View article: Nowhere to run, nowhere to hide ‐ targeting the immune system in AD with multimodal plasma therapeutics
Nowhere to run, nowhere to hide ‐ targeting the immune system in AD with multimodal plasma therapeutics Open
Background Age‐related diseases, especially Alzheimer’s Disease (AD), have multifaceted nature because of the different factors and pathways contributing to these diseases. Multi‐modal plasma therapies have the potential to impact multiple…
View article: Safety and tolerability of GRF6019 in mild‐to‐moderate Alzheimer's disease dementia
Safety and tolerability of GRF6019 in mild‐to‐moderate Alzheimer's disease dementia Open
Introduction This phase 2 trial evaluated the safety, tolerability, and feasibility of repeated infusions of the plasma fraction GRF6019 in mild‐to‐moderate Alzheimer's disease. Methods In this randomized, double‐blind, dose‐comparison tri…
View article: BENEFICIAL EFFECTS OF A PLASMA FRACTION ON NEUROGENESIS FOR AGE-RELATED COGNITIVE DISORDERS
BENEFICIAL EFFECTS OF A PLASMA FRACTION ON NEUROGENESIS FOR AGE-RELATED COGNITIVE DISORDERS Open
The process of aging is multifactorial and therefore single interventions may be unlikely to attenuate the myriad pathologies. Plasma contains many beneficial factors which have been shown in animal models to ameliorate multiple age-relate…